Vincristine

Generic Name: Vincristine

Brand Names: Marqibo, Vincasar

Drug Type: Small Molecule

Chemical Formula: C_₄₆H_₅₆N_₄O_₁₀

CAS Number: 57-22-7

Unique Ingredient Identifier: 5J49Q6B70F

Background: Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristin...

Indication: Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).

Associated Conditions: Acute Lymphoblastic Leukemia (ALL), Choriocarcinoma, Chronic Lymphocytic Leukemia, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Hepatoblastomas, Hodgkin's Lymphoma, Immune Thrombocytopenia (ITP), Kaposi's Sarcoma, Multiple Myeloma (MM), Neuroblastoma (NB), Non-Hodgkin's Lymphoma (NHL), Ovarian germ cell tumour, Pheochromocytoma, Relapsed Acute Lymphoblastic Leukemia (ALL), Retinoblastoma, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Wilms' tumor, Advanced Thymoma

Associated Therapies: -

Clinical Trials

Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers

Phase 2

Terminated

Conditions: Lymphoma
Leukemia
Myelodysplastic Syndrome
Myeloproliferative Disorders
Multiple Myleoma

Interventions: Drug: Rituximab
Drug: Fludarabine
Drug: Cyclophosphamide
Procedure: Peripheral blood stem cell (PBSC) transplantation
Drug: Etoposide
Genetic: T cell donor lymphocyte infusion (DLI) with unmanipulated donor T cells
Drug: Doxorubicin
Procedure: Allogeneic hematopoietic stem cell transplant (HSCT)
Drug: Vincristine
Drug: Filgrastim
Drug: Prednisone
Genetic: T-Rapa cell Donor Lymphocyte Infusion (DLI)

First Posted Date: 2003-12-15

Last Posted Date: 2018-12-31

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 442

Registration Number: NCT00074490

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States

Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia

Phase 2

Terminated

Conditions: Lymphoma

Interventions: Biological: rituximab
Drug: cyclophosphamide
Drug: Doxorubicin
Drug: Prednisone
Drug: Vincristine

First Posted Date: 2003-05-07

Last Posted Date: 2023-06-29

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 16

Registration Number: NCT00060346

Locations: 🇺🇸
Elkhart General Hospital, Elkhart, Indiana, United States
🇺🇸
Memorial Hospital of South Bend, South Bend, Indiana, United States
🇺🇸
Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States

and more 150 locations

PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: B-Cell Lymphoma

Interventions: Drug: PS-341
Drug: Etoposide
Drug: Doxorubicin
Drug: Vincristine
Drug: Cyclophosphamide
Drug: Prednisone
Drug: Filgrastim

First Posted Date: 2003-02-06

Last Posted Date: 2012-09-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 50

Registration Number: NCT00054665

Locations: 🇺🇸
Roswell Parck Cancer Institute, Buffalo, New York, United States
🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma

Phase 3

Completed

Conditions: Lymphoma

Interventions: Drug: Doxorubicin
Drug: Bleomycin
Drug: Vinblastine
Drug: Dacarbazine
Drug: Vincristine
Radiation: Radiotherapy
Drug: Mechlorethamine
Drug: Etoposide
Drug: Prednisone
Drug: Cyclophosphamide

First Posted Date: 2003-01-27

Last Posted Date: 2023-06-29

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 854

Registration Number: NCT00003389

Locations: 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada
🇺🇸
Piedmont Hospital, Atlanta, Georgia, United States
🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States

and more 529 locations

S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: filgrastim
Biological: rituximab
Drug: cyclophosphamide
Drug: cytarabine
Drug: dexamethasone
Drug: doxorubicin
Drug: leucovorin
Drug: methotrexate
Drug: vincristine

First Posted Date: 2003-01-27

Last Posted Date: 2012-11-01

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 56

Registration Number: NCT00041132

S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma

Phase 3

Active, not recruiting

Conditions: Lymphoma

Interventions: Drug: cyclophosphamide
Biological: rituximab
Drug: doxorubicin
Drug: prednisone
Drug: vincristine
Radiation: tositumomab

First Posted Date: 2003-01-27

Last Posted Date: 2024-06-24

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 571

Registration Number: NCT00006721

Locations: 🇺🇸
Northside Hospital Cancer Center, Atlanta, Georgia, United States
🇺🇸
Good Samaritan Regional Health Center, Mount Vernon, Illinois, United States
🇺🇸
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States

and more 254 locations

Low-Dose Radiation and Combination Chemotherapy Following Surgery in Children With Newly Diagnosed Medulloblastoma

Phase 2

Terminated

Conditions: Brain Tumors
Central Nervous System Tumors
Medulloblastoma

Interventions: Drug: Cisplatin
Drug: Cyclophosphamide
Drug: Etoposide
Drug: Lomustine
Drug: Vincristine
Radiation: Craniospinal Radiation

First Posted Date: 2003-01-27

Last Posted Date: 2019-04-25

Lead Sponsor: Children's Hospital of Philadelphia

Target Recruit Count: 30

Registration Number: NCT00031590

Locations: 🇺🇸
Lucile Packard Children's Hospital at Stanford University Medical Center, Palo Alto, California, United States
🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma: Hodgkin
Lymphoma, Hodgkin Disease
Hodgkin Disease
Lymphoma

Interventions: Drug: Vincristine
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Prednisone
Drug: Bleomycin
Drug: Etoposide
Radiation: Low-dose radiotherapy (RT)

First Posted Date: 2003-01-27

Last Posted Date: 2018-07-24

Lead Sponsor: Stanford University

Target Recruit Count: 76

Registration Number: NCT00026208

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
🇺🇸
Kaiser Permanente Medical Center, Vallejo, California, United States